Platelet count modulation

"Platelet count modulation" is not a specific molecule or receptor but rather refers to the physiological and molecular processes that regulate the number of circulating platelets in the blood. This process involves a complex interplay between **platelet production** by bone marrow megakaryocytes and **platelet clearance** from circulation. The primary molecular regulator is **thrombopoietin (TPO)**, which acts via its receptor c-Mpl on megakaryocytes and platelets to stimulate their survival, proliferation, and differentiation[2][3][5]. Additional regulatory mechanisms include glycan modifications on platelet surface proteins—particularly sialic acids—which influence platelet lifespan by targeting desialylated platelets for hepatic clearance through receptors such as the Ashwell–Morell receptor[2][7]. Genetic factors also play a role; genes like THPO, MPL, PIK3CG, PRKAR2B, GATA1, FOG1, and others are implicated in inherited variations in platelet counts[1]. Dysregulation can result in clinical conditions such as thrombocytopenia or thrombocytosis with associated risks of bleeding or thrombotic events. Because "platelet count modulation" describes a biological process rather than an individual targetable entity (such as a protein or receptor), it should not be considered a canonical therapeutic target itself. **Note:** For structured data purposes this entry is marked as incorrect because it does not refer to an individual molecule/receptor but rather to an entire regulatory process involving multiple targets[1][2][3].

Other names

Regulation of platelet countPlatelet number regulationThrombopoiesis regulation